Tenax Therapeutics Inc (TENX) News & EventsTENXNews & EventsTenax Therapeutics Inc

Tenax Therapeutics Presents New TNX-103 Trial Results

Tenax Therapeutics announced that additional results from the Phase 3 LEVEL clinical trial evaluating TNX-103 in patients with pulmonary hypertension due to heart failure with preserved ejection fraction, PH-HFpEF, were presented in a Late-Breaking Clinical Science session at the European Society of Cardiology, ESC, Congress 2026 in Munich, Germany. Key highlights: In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo; In the same patient population, TNX-103 produced a 47% reduction in NT-proBNP and a 4.9 mmHg reduction in RVSP compared to placebo; With full statistics analysis now complete, Company confirms TNX-103's biological effects include marked reductions in pulmonary artery pressure and NT-proBNP, a biomarker reflecting increased cardiac wall stress. Results will inform protocol population enrichment and changes to overall registrational path

Tenax Therapeutics Completes Randomization of 230 Patients for TNX-103

"We continued to make significant progress in advancing TNX-103, completing randomization of more than 230 patients in the Phase 3 LEVEL study at the end of the first quarter which positions us to deliver topline data in the third quarter of 2026," said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. "Our team continues to activate clinical sites around the world to advance the enrollment in LEVEL-2, our second pivotal trial of TNX-103. We are also thrilled to welcome Tom and Tim to our leadership team in key financial and commercial roles, further deepening the breadth of experience and knowledge at Tenax. Their appointments underscore our commitment to execution excellence as we advance the potential first therapy indicated for the treatment of PH-HFpEF."

Tenax Therapeutics Appoints Timothy Healey as Chief Commercial Officer

Tenax Therapeutics announced the appointment of Timothy Healey as chief commercial officer, effective immediately. Healey most recently served as chief commercial officer at Eversana Life Science Services.